The response of the prostate to circulating cholesterol: Activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kim, Jayoung ^a,b,c   Vizio, Dolores Di ^a,b,c   Kim, Taek Kyun ^d   Kim, Jonghwan ^e   Kim, Minjung ^f   Pelton, Kristine ^b   Clinton, Steven K ^g   Hai, Tsonwin ^h   Hwang, Daehee ^d   Solomon, Keith R ^b   Freeman, Michael R ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Pohang University of Science and Technology (POSTECH)   (South Korea)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CHOLESTEROL; ATF3 PROTEIN, HUMAN; ATF3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; HYPOCHOLESTEROLEMIA; IN VIVO STUDY; MALE; MALE GENITAL SYSTEM FUNCTION; MICROARRAY ANALYSIS; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PROSTATE; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURAL BIOINFORMATICS; VALIDATION PROCESS; ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; BLOOD; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ACTIVATING TRANSCRIPTION FACTOR 3; ADIPOSE TISSUE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; SIGNAL TRANSDUCTION;

EID: 84863611350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039448     Document Type: Article

References (56)

1. Moyad MA, Lowe FC, (2008) Educating patients about lifestyle modifications for prostate health. Am J Med 121: S34-42.
2. de Ferranti S, Mozaffarian D, (2008) The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 54: 945-955.
3. Marcovecchio M, Mohn A, Chiarelli F, (2005) Type 2 diabetes mellitus in children and adolescents. J Endocrinol Invest 28: 853-863.
4. Qi L, Saberi M, Zmuda E, Wang Y, Altarejos J, et al. (2009) Adipocyte CREB promotes insulin resistance in obesity. Cell Metab 9: 277-286.
5. Freeman MR, Solomon KR, (2004) Cholesterol and prostate cancer. J Cell Biochem 91: 54-69.
6. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR, (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115: 959-968.
7. Solomon KR, Pelton K, Boucher K, Joo J, Tully C, et al. (2009) Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 174: 1017-1026.
8. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB, (2012) Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One 7: e30062.
9. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ, (2004) The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394.
10. Murtola TJ, Tammela TL, Lahtela J, Auvinen A, (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16: 2226-2232.
11. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, et al. (2007) Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 16: 2218-2225.
12. Platz EA, Clinton SK, Giovannucci E, (2008) Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer 123: 1693-1698.
13. Parsons JK, Bergstrom J, Barrett-Connor E, (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101: 313-318.
14. Pelton K, Di Vizio D, Insabato L, Schaffner CP, Freeman MR, et al. (2010) Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol 184: 1555-1559.
15. Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, et al. (2003) A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res 63: 484-490.
16. Kim J, Adam RM, Freeman MR, (2005) Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stress. Cancer Res 65: 8242-8249.
17. Kim J, Jahng WJ, Di Vizio D, Lee JS, Jhaveri R, et al. (2007) The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res 67: 9229-9237.
18. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, et al. (2004) Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64: 8867-8875.
19. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, et al. (2007) Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 67: 6238-6246.
20. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
21. Hwang D, Rust AG, Ramsey S, Smith JJ, Leslie DM, et al. (2005) A data integration methodology for systems biology. Proc Natl Acad Sci U S A 102: 17296-17301.
22. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, et al. (2006) Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193: 1172-1177.
23. Junker BH, Koschutzki D, Schreiber F, (2006) Exploration of biological network centralities with CentiBiN. BMC Bioinformatics 7: 219.
24. Bergmann S, Ihmels J, Barkai N, (2004) Similarities and differences in genome-wide expression data of six organisms. PLoS Biol 2: E9.
25. Dong P, Flores J, Pelton K, Solomon KR, (2010) Prohibitin is a cholesterol-sensitive regulator of cell cycle transit. J Cell Biochem.
26. Thompson MR, Xu D, Williams BR, (2009) ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med 87: 1053-1060.
27. Hai T, Wolford CC, Chang YS, (2010) ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Expr 15: 1-11.
28. Hua B, Tamamori-Adachi M, Luo Y, Tamura K, Morioka M, et al. (2006) A splice variant of stress response gene ATF3 counteracts NF-kappaB-dependent anti-apoptosis through inhibiting recruitment of CREB-binding protein/p300 coactivator. J Biol Chem 281: 1620-1629.
29. Pan Y, Chen H, Siu F, Kilberg MS, (2003) Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter. J Biol Chem 278: 38402-38412.
30. Wang J, Cao Y, Steiner DF, (2003) Regulation of proglucagon transcription by activated transcription factor (ATF) 3 and a novel isoform, ATF3b, through the cAMP-response element/ATF site of the proglucagon gene promoter. J Biol Chem 278: 32899-32904.
31. Hashimoto Y, Zhang C, Kawauchi J, Imoto I, Adachi MT, et al. (2002) An alternatively spliced isoform of transcriptional repressor ATF3 and its induction by stress stimuli. Nucleic Acids Res 30: 2398-2406.
32. Chen BP, Liang G, Whelan J, Hai T, (1994) ATF3 and ATF3 delta Zip. Transcriptional repression versus activation by alternatively spliced isoforms. J Biol Chem 269: 15819-15826.
33. Saslowsky DE, Lawrence JC, Henderson RM, Edwardson JM, (2003) Syntaxin is efficiently excluded from sphingomyelin-enriched domains in supported lipid bilayers containing cholesterol. J Membr Biol 194: 153-164.
34. Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, et al. (2007) Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol 179: 3622-3630.
35. Rosenberger CM, Clark AE, Treuting PM, Johnson CD, Aderem A, (2008) ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells. Proc Natl Acad Sci U S A 105: 2544-2549.
36. Gilchrist M, Henderson WR Jr, Clark AE, Simmons RM, Ye X, et al. (2008) Activating transcription factor 3 is a negative regulator of allergic pulmonary inflammation. J Exp Med 205: 2349-2357.
37. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, et al. (2006) Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441: 173-178.
38. Suganami T, Yuan X, Shimoda Y, Uchio-Yamada K, Nakagawa N, et al. (2009) Activating transcription factor 3 constitutes a negative feedback mechanism that attenuates saturated Fatty acid/toll-like receptor 4 signaling and macrophage activation in obese adipose tissue. Circ Res 105: 25-32.
39. James CG, Woods A, Underhill TM, Beier F, (2006) The transcription factor ATF3 is upregulated during chondrocyte differentiation and represses cyclin D1 and A gene transcription. BMC Mol Biol 7: 30.
40. Li D, Yin X, Zmuda EJ, Wolford CC, Dong X, et al. (2008) The repression of IRS2 gene by ATF3, a stress-inducible gene, contributes to pancreatic beta-cell apoptosis. Diabetes 57: 635-644.
41. Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, et al. (2008) Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68: 8333-8341.
42. Kang Y, Chen CR, Massague J, (2003) A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 11: 915-926.
43. Lu D, Wolfgang CD, Hai T, (2006) Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281: 10473-10481.
44. Yin X, Dewille JW, Hai T, (2008) A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27: 2118-2127.
45. Pelzer AE, Bektic J, Haag P, Berger AP, Pycha A, et al. (2006) The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol 175: 1517-1522.
46. Ishiguro T, Nagawa H, (2001) ATF3 gene regulates cell form and migration potential of HT29 colon cancer cells. Oncol Res 12: 343-346.
47. Nickel JC, Elhilali M, Vallancien G, (2005) Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int 95: 571-574.
48. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, et al. (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44: 637-649.
49. Morote J, Lopez M, Encabo G, de Torres IM, (2000) Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol 37: 537-540.
50. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, et al. (2009) Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 182: 4056-4064.
51. Kim J, Yanagihara Y, Kikugawa T, Ji M, Tanji N, et al. (2009) A signaling network in phenylephrine-induced benign prostatic hyperplasia. Endocrinology 150: 3576-3583.
52. Kramer G, Marberger M, (2006) Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 16: 25-29.
53. Nickel JC, (2008) Inflammation and benign prostatic hyperplasia. Urol Clin North Am 35: 109-115; vii.
54. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M, (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33: 475-488.
55. Konig JE, Senge T, Allhoff EP, Konig W, (2004) Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 58: 121-129.
56. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M, (2004) Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 60: 153-159.